Drugmakers are promised expedited reviews of one to two months for new medicines that support “ national interests.”
WASHINGTON (AP) — A Democratic lawmaker is raising new concerns about a Food and Drug Administration program designed to drastically shorten the review of certain drugs, including whether senior officials involved in the effort are complying with federal ethics rules.
Additional Reads
Read Full Article: https://www.courthousenews.com/house-lawmaker-raises-new-concerns-over-fdas-ultra-fast-drug-review-program/
